You Position: Home > Paper
Insulin degluderc:A new generation of ultra-long-acting basal insulin analogue
( views:737, downloads:1327 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF DIABETES
- Issue:
- 8
- DOI:
- 10.3969/j.issn.1006-6187.2011.08.024
- Key Word:
- 德谷胰岛素;糖尿病;超长效基础胰岛素类似物
Abstract： 德谷胰岛素是新一代基础胰岛素类似物,通过经皮下注射后形成多六聚体,从而发挥超长效(>24h)作用.德谷胰岛素具有平坦的药代动力学曲线.相较于目前临床使用的基础胰岛素类似物能够更平稳的实现对血糖的控制.临床研究结果显示,德谷胰岛素在有效控制血糖的同时,还降低了治疗中的个体变异性及低血糖事件的发生.
- [1]Zinman B,Pinget M,Rao PV,etc.Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.[J].2011,377(9769).
- [2].The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus[J].1993.
- [3]Yang W,Lu J,Weng J,etc.Prevalence of diabetes among men and women in China.[J].2010,362(12).
- [4]Jendle JH,Roberts AP,Johansen T,etc.Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.[J].2011,34(3).
- [5].Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).[J].1998,352(9131).
- [6]Genuth SM,Raskin P,Nathan DM,etc.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.[J].2005,353(25).
- [7]Holman RR,Paul SK,Bethel MA,etc.10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes.[J].2008,359(15).